Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cabio Biotech (Wuhan) Co (688089) Fair Value & Analysis

Healthcare · CN · Market cap 2.0B CNY

Price¥11.56
Fair Value¥19.69
Upside+70.3%
Quality94/100
Evidence: High Range ¥12.72 – ¥24.42

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cabio Biotech (Wuhan) Co (688089) currently trades at ¥11.56, while our model-based Fair Value estimate is ¥19.69 — implying the stock looks roughly 70.3% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Cabio Biotech (Wuhan) Co (688089) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥19.69 versus a price of ¥11.56 — about +70% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 688089?
Our 21-model fair value for Cabio Biotech (Wuhan) Co is ¥19.69 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥11.56.
What is the quality score of 688089?
Cabio Biotech (Wuhan) Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.